» Articles » PMID: 33684560

Main Differences Between the First and Second Waves of COVID-19 in Madrid, Spain

Overview
Publisher Elsevier
Date 2021 Mar 8
PMID 33684560
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The emergence and rapid global spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) represents a major challenge to health services, and has disrupted social and economic activities worldwide. In Spain, the first pandemic wave started in mid-March 2020 and lasted for 3 months, requiring home confinement and strict lockdown. Following relaxation of the measures during the summer, a second wave commenced in mid-September 2020 and extended until Christmas 2020.

Methods: The two pandemic waves were compared using information collected from rapid diagnostic tests and polymerase chain reaction assays at one university clinic in Madrid, the epicentre of the pandemic in Spain.

Results: In total, 1569 individuals (968 during the first wave and 601 during the second wave) were tested for SARS-CoV-2-specific antibodies using fingerprick capillary blood. In addition, during the second wave, 346 individuals were tested for SARS-CoV-2-specific antigen using either oral swabs or saliva. The overall seroprevalence of first-time-tested individuals was 12.6% during the first wave and 7.7% during the second wave (P < 0.01). Seroconversions and seroreversions within 6 months occurred at low rates, both below 5%. During the second wave, 3.5% of tested individuals were SARS-CoV-2 antigen positive, with two cases considered as re-infections. Severe clinical symptoms occurred in a greater proportion of cases during the first wave compared with the second wave (27.8% vs 10.6%, respectively; P = 0.03).

Conclusion: The cumulative seroprevalence of SARS-CoV-2 antibodies in Madrid at the end of 2020 was approximately 20%. Seroreversions within 6 months occurred in 4% of cases. Seroconversions and re-infections were clinically less severe during the second wave than during the first wave. Hypothetically, a lower viral inoculum as a result of social distancing, increased use of face masks, promotion of outdoor activities and restrictions on gatherings may have contributed to this lower pathogenicity.

Citing Articles

Prediction of mortality and prioritisation to tertiary care using the 'OUR-ARCad' risk score gleaned from the second wave of COVID-19 pandemic-A retrospective cohort study from South India.

Gopalan N, Viswanathan V, Srinivasalu V, Arumugam S, Bhaskar A, Manoharan T PLoS One. 2025; 20(1):e0312993.

PMID: 39854588 PMC: 11761102. DOI: 10.1371/journal.pone.0312993.


Epidemiological Profile and Outcome of COVID-19 Patients and Its Comparison Between the First and Second Wave at a Tertiary-Level COVID Care Facility in North India.

Mishra P, Singh R, Nath A, Sanjeev O, Hashim Z, Dhiman R Cureus. 2024; 16(11):e74456.

PMID: 39726520 PMC: 11669753. DOI: 10.7759/cureus.74456.


Symptom propagation in respiratory pathogens of public health concern: a review of the evidence.

Asplin P, Mancy R, Finnie T, Cumming F, Keeling M, Hill E J R Soc Interface. 2024; 21(216):20240009.

PMID: 39045688 PMC: 11267474. DOI: 10.1098/rsif.2024.0009.


A comparative study between first three waves of COVID-19 pandemic with respect to risk factors, initial clinic-demographic profile, severity and outcome.

Thakur I, Chatterjee A, Ghosh A, Chatterjee S, Saha S, Panja T J Family Med Prim Care. 2024; 13(6):2455-2461.

PMID: 39027859 PMC: 11254042. DOI: 10.4103/jfmpc.jfmpc_1884_23.


Epidemiological and health economic implications of symptom propagation in respiratory pathogens: A mathematical modelling investigation.

Asplin P, Keeling M, Mancy R, Hill E PLoS Comput Biol. 2024; 20(5):e1012096.

PMID: 38701066 PMC: 11095726. DOI: 10.1371/journal.pcbi.1012096.


References
1.
Griffin D, Brennan-Rieder D, Ngo B, Kory P, Confalonieri M, Shapiro L . The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS Rev. 2021; 23(1):40-47. DOI: 10.24875/AIDSRev.200001261. View

2.
Thompson H, Mousa A, Dighe A, Fu H, Arnedo-Pena A, Barrett P . Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. Clin Infect Dis. 2021; 73(3):e754-e764. PMC: 7929012. DOI: 10.1093/cid/ciab100. View

3.
Babiker A, Marvil C, Waggoner J, Collins M, Piantadosi A . The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. J Clin Microbiol. 2020; 59(4). PMC: 8092746. DOI: 10.1128/JCM.02769-20. View

4.
Soriano V, Meirino R, Corral O, Guallar M . Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain. Clin Infect Dis. 2020; 72(6):1101-1102. PMC: 7337724. DOI: 10.1093/cid/ciaa769. View

5.
Soriano V, Sanchez-Santos M, Barreiro P . Rapid antigen Testing and Mask Wearing While Waiting for COVID-19 Vaccines. AIDS Rev. 2020; 22(3):168-172. DOI: 10.24875/AIDSRev.M20000038. View